Reports received by FDA, by month
March 2004: adverse event reports received by FDA
14,823 drug reports (FAERS) and 7,204 device reports (MAUDE).
- 14,823
- drug reports received
- —
- monthly average, preceding 12 months
- 7,204
- device reports received
- 6,765 a year earlier
FDA received 14,823 drug adverse event reports in March 2004. The MAUDE device database received 7,204 reports that month (6,765 a year earlier).
The drugs listed most often as suspect products were Ortho Evra (1,459), Humira (809) and Strattera (755), and the reactions recorded most often were nausea (882), headache (617) and vomiting (587).
Drug reports by month, three years to March 2004
Drugs listed most often as suspect products
| Drug | Reports | Share of the month |
|---|---|---|
| Ortho Evra | 1,459 | 9.8% |
| Humira | 809 | 5.5% |
| Strattera | 755 | 5.1% |
| Forteo | 703 | 4.7% |
| Advair Diskus 100/50 | 350 | 2.4% |
| Remicade | 284 | 1.9% |
| Cialis | 261 | 1.8% |
| Crestor | 235 | 1.6% |
| Thalomid | 202 | 1.4% |
| Ortho Tri-Cyclen Lo | 202 | 1.4% |
| Paxil | 201 | 1.4% |
| Levitra | 175 | 1.2% |
| Duragesic | 157 | 1.1% |
| Zetia | 125 | 0.8% |
| Vioxx | 122 | 0.8% |
FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Reactions recorded most often
| MedDRA term | Reports | Share of the month |
|---|---|---|
| Nauseafeeling sick | 882 | 6% |
| Headachehead pain | 617 | 4.2% |
| Vomitingbeing sick | 587 | 4% |
| Dizzinesslight-headedness or unsteadiness | 558 | 3.8% |
| Drug ineffectivethe medicine did not work as expected | 555 | 3.7% |
| Metrorrhagia | 473 | 3.2% |
| Astheniaweakness or lack of energy | 461 | 3.1% |
| Dyspnoeashortness of breath | 449 | 3% |
| Fatiguetiredness | 439 | 3% |
| Pyrexiafever | 412 | 2.8% |
| Diarrhoealoose or frequent stools | 374 | 2.5% |
| Pharmaceutical product complaint | 371 | 2.5% |
| Medication errora mistake in prescribing, dispensing or taking a medicine | 349 | 2.4% |
| Abdominal painstomach or belly pain | 341 | 2.3% |
| Feeling abnormalfeeling odd or not right | 310 | 2.1% |
Devices named most often
| Brand | Reports | Share of device reports |
|---|---|---|
| One Touch Ultra | 372 | 5.2% |
| Cypher Sirolimus-Eluting Coronary Stent | 252 | 3.5% |
| Minimed Infusion Pump | 173 | 2.4% |
| M Series | 171 | 2.4% |
| Ligaclip Endoscopic Rotating Multiple Clip Applier | 121 | 1.7% |
| Fasttake | 106 | 1.5% |
| Hydroview Intraocular Lens | 106 | 1.5% |
| Guidant 4 5 Mm Heartstring Proximal Seal | 80 | 1.1% |
| Colleague Volumetric Infusion Pump | 76 | 1.1% |
| Synchromed El | 71 | 1% |
Questions about March 2004
How many adverse event reports did FDA receive in March 2004?
14,823 drug reports are in the openFDA FAERS release of 28 Sep 2026, and 7,204 device reports in the MAUDE release of 28 Sep 2026.
Which drugs were listed most often?
Ortho Evra (1,459), Humira (809), Strattera (755), Forteo (703) and Advair Diskus 100/50 (350).
Which reactions were recorded most often?
nausea (882), headache (617), vomiting (587), dizziness (558) and drug ineffective (555).
Can the count for a month still change?
Yes. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Older months change little.
Does a busy month mean something happened that month?
Not by itself. The date is when FDA received the report, not when the event occurred, and volume follows manufacturer batches, product launches and publicity. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.